Effectiveness of Buspirone & Motivational Enhancement Therapy for

Status Completed

Clinical Trial Summary

This study will assess the effectiveness of a combination of buspirone and motivational interviewing therapy in the treatment of marijuana dependence.

Clinical Trial Description

Marijuana dependence is one of the most common substance-related disorders in the United States. Despite its prevalence, there is a lack of clinical research addressing treatments for marijuana dependence. Research has shown that marijuana abuse is associated with affective disorders. This may be caused by repeated use for relief from anxiety. The use of an anxiolytic agent, a drug that relieves anxiety, may help treat marijuana dependence. Motivational enhancement therapy has been shown to reduce marijuana use. Therefore, it is likely that buspirone, which is an anxiolytic agent, combined with motivational enhancement therapy will prove beneficial in treating marijuana dependence. This study will assess the effectiveness of a combination of buspirone and motivational interviewing in the treatment of marijuana dependence.

This double-blind study will last a total of 16 weeks. Participants will be randomly assigned to receive either buspirone or placebo for a period of 12 weeks. There will be one follow-up appointment 4 weeks post-intervention. Baseline assessments will include a physical exam and urine and blood tests. Study visits will occur weekly throughout treatment in order to monitor compliance, assess adverse affects, and obtain substance use data. Mood assessment scales, marijuana craving questionnaires, and a withdrawal symptom checklist will be used to gather the data. Urine drug screens will be collected weekly to test for marijuana use. In addition to this, the presence of opioids, cocaine, amphetamines, and benzodiazepines will be tested at baseline, Weeks 6 and 12, and at follow-up. A 10-day supply of medication will be dispensed to participants each week. Meetings for motivational enhancement therapy will last 30 to 90 minutes each and will occur at baseline, Week 2, and Week 4. Participants' perceived quality of life will be measured at baseline and Weeks 6 and 12 to determine the effect of buspirone. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00149617
Study type	Interventional
Source	Medical University of South Carolina
Contact
Status	Completed
Phase	Phase 2
Start date	April 2004
Completion date	December 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05321602` - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder	Phase 1
Recruiting	`NCT05345392` - Brain, Emotions, and Mind-Wandering	N/A
Completed	`NCT05078450` - Mood Lifters Online for Graduate Students and Young Professionals	N/A
Not yet recruiting	`NCT04551027` - Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness	N/A
Recruiting	`NCT03088657` - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
Active, not recruiting	`NCT02542475` - Low Field Magnetic Stimulation: Open Label Study.	Phase 1/Phase 2
Completed	`NCT00916552` - Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder	Phase 2
Completed	`NCT00202514` - Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms	Phase 2/Phase 3
Completed	`NCT00217932` - Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings	Phase 2
Completed	`NCT00006517` - Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)	N/A
Terminated	`NCT03898843` - Assisted Animal Therapy: ReAnimal	N/A
Active, not recruiting	`NCT04358900` - Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)
Recruiting	`NCT06360562` - Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)	N/A
Completed	`NCT05745103` - Optimizing Behavioral Healthcare Delivery Through Technology	N/A
Suspended	`NCT03715400` - Mobile Virtual Positive Experiences for Anhedonia	N/A
Enrolling by invitation	`NCT03736538` - Nitrous Oxide- Suicidal Ideation	Phase 1
Completed	`NCT04601545` - The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method	N/A
Completed	`NCT02566980` - Biological Triggers of Depression in Pregnancy
Completed	`NCT03743844` - Psychosocial Intervention for Women With Mood Disorders Seeking Treatment for Obesity	N/A
Completed	`NCT05211063` - Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms